LeadIQ logo
Learn more at LeadIQ.com

Insights

Expansion into Asia-Pacific Myeloid Therapeutics launched Aurora Biosynthetics to meet RNA therapeutics demand in Asia-Pacific, indicating potential opportunities for market expansion and collaboration in this region.

Key Personnel Appointments Recent appointments of Robert Hofmeister as Chief Scientific Officer and Matthew Maurer as Chief Medical Officer suggest a strengthening of leadership, opening avenues for strategic partnerships and business development initiatives.

Cutting-Edge Facility Launch The launch of a state-of-the-art GMP manufacturing RNA facility showcases a commitment to advanced technology and production capabilities, presenting opportunities for partnerships and contract manufacturing agreements.

Clinical Development Support Myeloid Therapeutics raised $73 million to support clinical development, signaling financial stability and potential for collaborations or investments from entities looking to support innovative therapies.

Focused Pipeline Development Development of MT-101, a lead cell therapy program in Phase I/II trials for T cell lymphoma, highlights a focused approach to therapeutic innovations, creating opportunities for strategic alliances and licensing agreements.

Similar companies to Myeloid Therapeutics

Myeloid Therapeutics Tech Stack

Myeloid Therapeutics uses 8 technology products and services including MySQL, Google Cloud, RequireJS, and more. Explore Myeloid Therapeutics's tech stack below.

  • MySQL
    Database
  • Google Cloud
    Infrastructure As A Service
  • RequireJS
    Javascript Frameworks
  • Slick
    Javascript Libraries
  • Open Graph
    Miscellaneous
  • PHP
    Programming Languages
  • Cloudflare Bot Management
    Security
  • Contact Form 7
    Web Platform Extensions

Media & News

Myeloid Therapeutics's Email Address Formats

Myeloid Therapeutics uses at least 1 format(s):
Myeloid Therapeutics Email FormatsExamplePercentage
FLast@myeloidtx.comJDoe@myeloidtx.com
91%
FMiddleLast@myeloidtx.comJMichaelDoe@myeloidtx.com
4%
First@myeloidtx.comJohn@myeloidtx.com
3%
FirstLast@myeloidtx.comJohnDoe@myeloidtx.com
2%

Frequently Asked Questions

Where is Myeloid Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Myeloid Therapeutics's main headquarters is located at 300 Technology Sq 2nd Floor Cambridge, Massachusetts 02139 US. The company has employees across 2 continents, including North AmericaEurope.

What is Myeloid Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Myeloid Therapeutics's official website is myeloidtx.com and has social profiles on LinkedIn.

How much revenue does Myeloid Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2024, Myeloid Therapeutics's annual revenue reached $3.8M.

What is Myeloid Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Myeloid Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Myeloid Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2024, Myeloid Therapeutics has approximately 53 employees across 2 continents, including North AmericaEurope. Key team members include Chief People Officer: C. D.Chief Scientific Officer: R. H.Chief Medical Officer: M. M.. Explore Myeloid Therapeutics's employee directory with LeadIQ.

What industry does Myeloid Therapeutics belong to?

Minus sign iconPlus sign icon
Myeloid Therapeutics operates in the Biotechnology Research industry.

What technology does Myeloid Therapeutics use?

Minus sign iconPlus sign icon
Myeloid Therapeutics's tech stack includes MySQLGoogle CloudRequireJSSlickOpen GraphPHPCloudflare Bot ManagementContact Form 7.

What is Myeloid Therapeutics's email format?

Minus sign iconPlus sign icon
Myeloid Therapeutics's email format typically follows the pattern of . Find more Myeloid Therapeutics email formats with LeadIQ.

How much funding has Myeloid Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2024, Myeloid Therapeutics has raised $73M in funding. The last funding round occurred on May 18, 2023 for $73M.
Myeloid Therapeutics

Myeloid Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer.

We invite you to join us on this journey – patients are waiting.   

 

Section iconCompany Overview

Headquarters
300 Technology Sq 2nd Floor Cambridge, Massachusetts 02139 US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $73M

    Myeloid Therapeutics has raised a total of $73M of funding over 3 rounds. Their latest funding round was raised on May 18, 2023 in the amount of $73M.

  • $10M

    Myeloid Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $73M

    Myeloid Therapeutics has raised a total of $73M of funding over 3 rounds. Their latest funding round was raised on May 18, 2023 in the amount of $73M.

  • $10M

    Myeloid Therapeutics's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.